Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terbogrel in primary pulmonary hypertension
NCT02223494Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 1998
- Primary completion
- Mar 2000
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of terbogrel in pulmonary arterial hypertension (PAH), sponsored by Boehringer Ingelheim. Started Oct 1998; status: terminated.
02
Drugs
terbogrel
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02223494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223494.